Ria Organics proposes an API intermediates manufacturing unit in dist. Pune, Maharashtra

August 5, 2016

Drugs and Pharmaceuticals

Status: Conceptual

Promoter: Ria Organics

Project: Proposes a 42.8 TPA API intermediates manufacturing unit

Location: Kurkumbh MIDC, dist. Pune, Maharashtra

Project Details: The current status of the project could not be ascertained. According to MoEF sources, Sadekar Enviro Engineers is the consultant. The plot area is 8,000 sq. mtrs and the greenbelt area is 1,320 sq. mtrs. Estimated cost of the project is Rs. 140 million. Power requirement is 380 kVA, which will be sourced from MSEDCL. The company will establish a full-fledged ETP of 60 CMD capacity comprising of tertiary treatment scheme.


Shantha Biotechnics has commissioned a new vaccine production facility in Telangana

July 7, 2016

Drugs & Pharma

Status: Commissioned

Promoter: Shantha Biotechnics

Project: Commissioned a new vaccine production facility

Location: Village Muppireddypally, dist. Medak, Telangana.

Project Details: Construction of the 19,000 sq. mtrs facility began in 2010 and the site is now ready for operations post approval from the Indian regulatory authorities and the World Health Organization. The new filling facility will be used for producing vaccines against multiple diseases, starting with Shan5, pediatric pentavalent vaccine, which provides protection against five diseases in one shot. This site is a part of over Rs. 55,000 million investments undertaken by Sanofi since acquisition of Shantha Biotechnics. Commercial production commenced on 25th May, 2016. An insulin plant being set up with Rs. 4,500 million by the company in the same location is expected to be ready in about a year. According to media reports, the cost of the project is Rs. 2,500 million. This year’s target is to produce 10 million doses of vaccine in the new plant but it could be scaled up to produce up to 30 million doses going forward. It will be used to cater to the requirements of Sanofi as well domestic market.

Central Research Institute inaugurated the Current Good Manufacturing Practise compliant facility in dist. Solan, Himachal Pradesh.

May 3, 2016

Drugs and Pharmaceuticals

Status: Commissioned

Promoter: Central Research Institute (CRI)

Project: Inaugurated the Current Good Manufacturing Practise (CGMP) compliant facility

Location: CRI, Kasauli, dist. Solan, Himachal Pradesh

Project Details: The institute was inaugurated on 24th April, 2016. The facility will be for the manufacture of DPT and TT vaccine. TT vaccine has been commercialized from this facility for Universal Immunization Programme use and production of DPT bulk has been initiated. CRI is exploring the feasibility of establishing WHO prequalified cGMP compliant manufacturing facility for yellow fever vaccine. This will enable the institute to supply yellow fever vaccine to African and Latin American countries. The institute has plans to manufacture all vaccines viz., Japanese encephalitis vaccine, rabies vaccine and typhoid vaccine, which were earlier manufactured in the Institute, after establishing CGMP compliant facilities and application of recent technological advancements. CRI plans to create state of the art, fully dedicated CGMP compliant laboratory for research on vaccine development and various other public health related issues. The institute plans to undertake research on newer vaccine candidates for existing and emerging diseases and to manufacture more efficacious and safer vaccines. CRI is in process of acquiring 128 bighas of land from Himachal Pradesh Government for creation of CGMP compliant facility for manufacturing of therapeutic anti-sera. CRI has started apprenticeship training for maintenance of high end machinery and equipment that have been installed with creation of new cGMP facility for production of DPT vaccine in the institute. The institute is involved in manufacture and supply of various lifesaving therapeutic antisera for snake bites, rabies and diphtheria, and supplies yellow fever vaccine to different parts of the country. Diagnostic reagents such as diagnostic antigens for typhoid, typhus fever and brucellosis and diagnostic antisera for cholera and salmonella are also manufactured and supplied to various institutions.

Somu Chemicals And Pharmaceuticals has commissioned a herbal extract and API manufacturing unit in Karnataka

April 5, 2016

Drugs and Pharma

Status: Commissioned

Promoter: Somu Chemicals And Pharmaceuticals, a part of Somu Group

Project: Commissioned a 65,000 kgs/ yr herbal extract and active pharmaceutical ingredient manufacturing unit

Location: Anekal Taluka, dist. Bengaluru, Karnataka

Project Details: The project is spread over on 10,000 sq. ft. The estimated cost of the project is Rs. 34.2 million. Commercial production commenced in February 2016. According to MoEF sources, the products include 14,000 kgs/ yr herbal extracts, 51,000 kgs/ yr cosmetics ingredients, nutraceutical ingredients, pharma intermediates and API with R&D activity. Effluent generated will be treated in common effluent treatment plant. The total power requirement of the industry is 65 kVA. Greenbelt will be developed in 30% of the total area.

Nakoda Chemicals is planning an expansion of its bulk drug manufacturing unit in dist. Rangareddy, Telangana.

December 5, 2015

Drugs and Pharmaceuticals

Status: Planning Stage

Promter: Nakoda Chemicals

Planning an expansion of its bulk drug manufacturing unit from its existing capacity of 34.2 TPA to 141.16 TPA.

Location: IDA Jeedimetla, dist. Rangareddy, Telangana

Current Status: The project is waiting for environmental clearance.

Parenteral Drugs (India) is relocating its drugs manufacturing unit from dist. Indore to dist. Khargone, Madhya Pradesh.

December 5, 2015

Drugs and Pharmaceuticals

Status: Under Implementation

Promoter: Parenteral Drugs (India)

Project: Relocation of drugs manufacturing unit.

Project Details: The plant is being relocated from Village Asrawad, Post Dudhia, Nemawar Road, dist. Indore to Village Panwa, Tehsil Kasrawad, dist. Khargone. The company has initiated the process of relocation of the plant in April 2015 and for the purpose of relocation of the same, since, the civil work has almost been completed for its IV Fluids and allied manufacturing activities, the company has discontinued its manufacturing operations at Village Asrawad with effect from 24th August, 2015.

Mankind Pharma is planning a pharmaceuticals & food formulations manufacturing unit in Sikkim.

November 18, 2015

Durgs and Pharmaceuticals

Status: Conceptual Stage

Promoter: Mankind Pharma

Project: Plans a pharmaceuticals & food formulations manufacturing unit

Location: Sikkim

Project Details: The project is in initial stage of planning.